摘要
控制免疫系统主动攻击肿瘤组织的能力将会是一种与癌症持续攻击博斗的非凡武器。不幸的是,癌症治疗还没有可以获得这种控制力的安全有效方法。为了克服这种控制的障碍,白介素12 (IL-12)肿瘤靶向质粒DNA可以被安全投递到常见肿瘤,并且这些治疗可以诱导处理后和未经处理的肿瘤的抗癌免疫应答。在此,电穿孔介导的ttIL-12pDNA在犬自然发生肿瘤的剂量递增研究中表现出安全且耐受性良好。在剂量递增研究中存活的犬给予3800 μg pDNA,分配于 5种独立的犬磷状细胞癌,相当于I期临床试验服用的野生型IL-12 pDNA剂量。任何一个病人在5种不同剂量水平下未发生严重不良事件,并且参数测试只记录了轻微短暂的变化。在治疗与未治疗的病灶中的临床反应分析和mRNA免疫标志物检测暗示:ttIL-12 pDNA 治疗在少数肿瘤中可以引起病灶治疗及远处转移病灶的抗肿瘤免疫应答。这些观察结果表明ttIL-12 pDNA临床剂量可以被安全服用,并且 这些治疗会影响处理过和未处理的转移灶。
关键词: 癌症,犬,电穿孔,基因治疗,免洗疗法,白细胞介素12,肿瘤靶向
Current Gene Therapy
Title:Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions
Volume: 15 Issue: 1
Author(s): Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia and Shulin Li
Affiliation:
关键词: 癌症,犬,电穿孔,基因治疗,免洗疗法,白细胞介素12,肿瘤靶向
摘要: The ability to control the immune system to actively attack tumor tissues will be a marvelous weapon to combat the persistent attack of cancer. Unfortunately, safe and effective methods to gain this control are not yet available as cancer therapies. To overcome the impediments to this control, tumor-targeted (tt) Interleukin 12 (IL-12) plasmid DNA can be safely delivered to accessible tumors, and these treatments can induce antitumor immune responses in both the treated and untreated tumors. Here, electroporationmediated ttIL-12 pDNA treatments are shown to be safe and well tolerated in a dose escalation study in canines bearing naturally-occurring neoplasms. The final patient in the dose-escalation study received up to 3,800 μg pDNA distributed among five separate squamous cell carcinoma tumors in doses equivalent to those administered in a Phase I trial with wildtype IL-12 pDNA. Not a single severe adverse event occurred in any patient at any of the five dose levels, and only minor, transient changes were noted in any tested parameter. Clinical response analysis and immune marker mRNA detection of treated and non-treated lesions suggest that ttIL-12 pDNA treatments in only a few tumors can elicit antitumor immune responses in the treated lesions as well as distant metastatic lesions. These observations and results demonstrate that ttIL-12 pDNA can be safely administered at clinical levels, and these treatments can affect both treated and nontreated, metastatic lesions.
Export Options
About this article
Cite this article as:
Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia and Shulin Li , Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127093654
DOI https://dx.doi.org/10.2174/1566523214666141127093654 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Theranostics Based on Iron Oxide and Gold Nanoparticles for Imaging- Guided Photothermal and Photodynamic Therapy of Cancer
Current Topics in Medicinal Chemistry NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients
Current Proteomics Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Biomarkers IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets